The Effect of Terazosin and Tolterodine on Ureteral Stent Related Symptoms
- Conditions
- Disorder of Urinary Stent
- Interventions
- Registration Number
- NCT01530243
- Lead Sponsor
- Urmia University of Medical Sciences
- Brief Summary
The aim of the investigators study is to evaluate whether alpha-blockers such as terazosin and anti-cholinergics such as tolterodine can be relieve the DJ-stent related symptoms.
- Detailed Description
Ureteral stent (US) has been as essential tool in the urologist's surgeries and is useful instruments that its indications increase due to new stent technologies and improvement of patient's comfort.
US associated with discomfort complications that include lower urinary tract symptoms (LUTS) as frequency, urgency, dysuria, incomplete emptying, flanks and suprapubic's pain, incontinence, hematuria, movement of stent, infection and encrustation of stent. US related symptoms are as same as LUTS due to benign prostate hyperplasia and overactive bladder which relieve with alpha-blockers and anticholinergic. The purpose of our study is to investigate the effect of terazosin and tolterodine lonely and together in comparison of placebo on US related symptoms.
The investigators study will be done prospectively. The patients who underwent indwelling Double-j stent distributed into four groups: 1)receive placebo 2)receive terazosin 2mg twice 3)receive tolterodine 2mg daily 4) receive terazosin 2mg twice and tolterodine 2mg daily. All of the patients receive prophylactic antibiotic and on demand analgesic. After entrance to study, they fulfill the International Prostatic Symptoms Score (IPSS) and Visual Analog Scale (VAS) on the before indwelling US, two weeks after indwelling US and US removal time, then the investigators will evaluate the drug's effect on US related symptoms.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 104
If a patient does not meet any exclusion criteria and to be undergone double-J stent indwelling.
- Prior history of pelvic surgery
- Prior history of Transurethral Resection of the either Prostate or Bladder Tumor
- Benign prostate hyperplasia
- Recent or recurrent urinary tract infection
- Chronic medication with beta-blockers or Anti-cholinergic
- Pregnancy
- Prostatitis
- Prostate cancer
- Bilateral ureteroscopy or ureteral stenting
- Age < 18 and > 55
- Stone size > 20 mm
- Diabetes
- Bladder Outlet Obstruction
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Tolterodine Tolterodine - Placebo Placebo - Terazosin Terazosine - Tolterodine + Terazosin Tolterodine + Terazosin -
- Primary Outcome Measures
Name Time Method Lower Urinary Tract Symptoms (LUTS) Expected average of 2 weeks LUTS was evaluated using the International Prostate Symptom Score (IPSS) questionnaire perioperatively. The IPSS constitutes of seven questions assigned score from 0 to 5 to evaluate the severity of LUTS in patients. Total scoring of IPSS ranges from 0 to 35, asymptomatic to very symptomatic. The more the score on scale is, the worse the outcome is.Therefore, the higher values represent worse outcomes.
- Secondary Outcome Measures
Name Time Method Quality of Life Expected 2 weeks later The Quality of life of patients was evaluated using single question in IPSS questionnaire in which each of patients received scoring from 0 to 6. The higher values represent the worse quality of life.
Trial Locations
- Locations (1)
Imam Khomeini Hospital
🇮🇷Urmia, Azerbaijan-gharbi, Iran, Islamic Republic of